Medgenics Inc - MDGN - reported that it has received notice of 'Intention to Grant' from the European Patent Office for the patent application entitled "USE OF DERMAL MICRO ORGANS," with allowed claims covering a core element of its Biopump protein therapy technology. This follows Similar U.S. Patent for Biopump Protein Therapy Technology and Expands Medgenics' Intellectual Property Portfolio. Medgenics is developing and commercializing Biopump, a proprietary tissue-based platform technology for the sustained production and delivery of therapeutic proteins using the patient's own skin biopsy for the treatment of a range of chronic diseases including anemia, hepatitis C and hemophilia. ********************************* THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY! (Read Full Disclaimer at http://www.crwenewswire.com/disclaimer)

• Added by: karmastock
• Date added: 22/01/12
• Video Duration: 01:14
• Category: News
• Number of views: 188
• Tags: Amex:MDGN, Anemia, Biopump, european patent office, hemophilia, Hepatitis C, MDGN, Medgenics, skin biopsy, therapeutic proteins Medgenics (MDGN) Gets Allowance for Key European Patent



Post a Comment

To add a comment, please fill out the box below and click on the submit button. Comment:

There are currently no comments for this video